SK15422002A3 - Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou - Google Patents

Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou Download PDF

Info

Publication number
SK15422002A3
SK15422002A3 SK1542-2002A SK15422002A SK15422002A3 SK 15422002 A3 SK15422002 A3 SK 15422002A3 SK 15422002 A SK15422002 A SK 15422002A SK 15422002 A3 SK15422002 A3 SK 15422002A3
Authority
SK
Slovakia
Prior art keywords
day
dose
galantamine
weeks
followed
Prior art date
Application number
SK1542-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica N. V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N. V. filed Critical Janssen Pharmaceutica N. V.
Publication of SK15422002A3 publication Critical patent/SK15422002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
SK1542-2002A 2000-04-03 2001-03-28 Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou SK15422002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
SK15422002A3 true SK15422002A3 (sk) 2003-04-01

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1542-2002A SK15422002A3 (sk) 2000-04-03 2001-03-28 Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou

Country Status (20)

Country Link
EP (1) EP1272192A2 (hu)
JP (1) JP2003528913A (hu)
KR (1) KR20020086911A (hu)
CN (1) CN1430514A (hu)
AU (2) AU2001265844B2 (hu)
BG (1) BG107093A (hu)
BR (1) BR0109770A (hu)
CA (1) CA2310926C (hu)
CZ (1) CZ20023543A3 (hu)
EE (1) EE200200554A (hu)
HR (1) HRP20020778A2 (hu)
HU (1) HUP0300566A3 (hu)
IL (1) IL152061A0 (hu)
MX (1) MXPA02009777A (hu)
NO (1) NO20024746L (hu)
PL (1) PL361272A1 (hu)
RU (1) RU2002129298A (hu)
SK (1) SK15422002A3 (hu)
WO (1) WO2001074339A2 (hu)
ZA (1) ZA200207935B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
AU2004262897B9 (en) 2003-07-25 2009-12-17 F. Hoffmann-La Roche Ag Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
MX344177B (es) 2008-03-27 2016-12-08 Chase Pharmaceuticals Corp Uso y composicion para tratar la demencia.
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
CN107847504A (zh) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 淀粉状蛋白β的加兰他敏清除
WO2023036105A1 (zh) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
WO2000030446A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
SI1140105T1 (en) * 1998-12-24 2004-04-30 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects

Also Published As

Publication number Publication date
MXPA02009777A (es) 2003-03-27
HRP20020778A2 (en) 2004-04-30
CA2310926A1 (en) 2000-10-04
NO20024746L (no) 2002-11-28
HUP0300566A2 (hu) 2003-06-28
AU2001265844B2 (en) 2005-04-14
WO2001074339A2 (en) 2001-10-11
BG107093A (bg) 2003-06-30
ZA200207935B (en) 2004-01-30
IL152061A0 (en) 2003-05-29
AU6584401A (en) 2001-10-15
RU2002129298A (ru) 2004-03-27
JP2003528913A (ja) 2003-09-30
BR0109770A (pt) 2003-02-04
HUP0300566A3 (en) 2004-10-28
CN1430514A (zh) 2003-07-16
EP1272192A2 (en) 2003-01-08
CZ20023543A3 (cs) 2003-03-12
CA2310926C (en) 2002-10-15
WO2001074339A3 (en) 2002-09-12
EE200200554A (et) 2004-04-15
PL361272A1 (en) 2004-10-04
KR20020086911A (ko) 2002-11-20
NO20024746D0 (no) 2002-10-02

Similar Documents

Publication Publication Date Title
Tandon et al. Muscarinic cholinergic hyperactivity in schizophrenia: relationship to positive and negative symptoms
Santosh et al. Psychopharmacotherapy in children and adults with intellectual disability
JP2018002738A (ja) ムスカリン性受容体活性化によって改善される疾患の治療のための方法および組成物
CA2310950C (en) An efficacious dosage regiment of galantamine that reduces side effects
KR20010102460A (ko) 운동 유발 천식의 치료 방법
US20220184074A1 (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
SK15422002A3 (sk) Použitie galantamínu na liečenie neuropsychických porúch spojených s Alzheimerovou chorobou
AU2022252766A1 (en) Treatment of hand eczema
Pollock et al. Antipsychotics in older patients: a safety perspective
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
KR20010102459A (ko) Ｃｏｐｄ의 치료 방법
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
Thornton Sleep aids and sedatives
KORSANTIA et al. PEMPHIGUS VULGARIS, CURRENT STATUS AND PROSPECTS
US20210023091A1 (en) Treatment of conditions associated with myotonic dystrophy
EP4301367A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
CA3144067A1 (en) Lemborexant for treating sleep issues
Walsh Antihistamines (H1 receptor antagonists)
Allegaert et al. PROCEEDINGS OF THE DUTCH SOCIETY OF CLINICAL PHARMACOLOGY AND BIOPHARMACY MEETING OF OCTOBER 4TH 2005